Clinical Trials on Recurrent Prostate Cancer in Colombia

Total 2593 results

Myrexis Inc.

Unknown

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

Prostate Cancer

United States
US Oncology Research
Eli Lilly and Company; Oregon Health and Science University

Completed

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

Androgen-independent Prostate Cancer

United States
British Columbia Cancer Agency
Canadian Institutes of Health Research (CIHR)

Completed

18F-NaF PET Imaging for Bone Scintigraphy

Bone Metastases From Breast or Prostate Cancer

Canada
Dendreon

Completed

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED)

Prostatic Neoplasms | Advanced Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
NCIC Clinical Trials Group

Completed

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Prostate Cancer

Canada
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Prostate Cancer

Canada
Bavarian Nordic

Completed

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Prostate Cancer Metastatic

United States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
Medical University of South Carolina

Terminated

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Prostate Cancer

United States
EMD Serono

Completed

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (PERSEUS)

Prostate Cancer Metastatic

United States, Australia, France, Poland, Russian Federation, Spain, Germany, Netherlands, Slovakia, Canada, South Africa, Belgium
University Health Network, Toronto
Sunnybrook Health Sciences Centre; Tom Baker Cancer Centre; Vancouver Coastal... and other collaborators

Active, not recruiting

Sexual Health and Rehabilitation eClinic (SHAReClinic)

Sexual Dysfunction | Prostate Cancer

Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Metastatic Hormone Refractory Prostate Cancer

United States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels

Prostate Cancer

United States
British Columbia Cancer Agency
Ferring Pharmaceuticals

Unknown

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Prostate Neoplasm

Canada
Hinova Pharmaceuticals USA, Inc.

Active, not recruiting

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Germany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria
Vancouver Prostate Centre

Active, not recruiting

Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Prostate Cancer (EMMPC)

Prostate Cancer

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Howard University; Prostate Cancer Clinical Trials Consortium

Completed

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

Prostate Cancer

United States
Genzyme, a Sanofi Company

Terminated

Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy (ZENITH)

Prostate Cancer

Canada
Coherus Biosciences, Inc.
Arcus Biosciences, Inc.; Surface Oncology

Terminated

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Canada
Amgen

Completed

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Carcinoma | Cancer | Prostate Cancer | Tumors | Castrate-Resistant Prostate Cancer

United States, Canada, Poland, Hungary, Finland, Mexico
University of British Columbia
British Columbia Cancer Agency

Active, not recruiting

Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT)

Prostate Cancer

Canada
GlaxoSmithKline

Completed

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

Neoplasms

United States, United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditions

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Georgetown University
National Cancer Institute (NCI)

Completed

Streamlined Genetic Testing in Prostate Cancer

Prostate Cancer

United States
CHU de Quebec-Universite Laval
TerSera Therapeutics LLC

Recruiting

Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer. (PCS-XI)

Prostate Cancer | Radiotherapy Side Effect | Node; Prostate

Canada
Achieve Life Sciences

Completed

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Prostate Cancer

Canada
Canadian Cancer Trials Group
Canadian Cancer Society (CCS)

Recruiting

Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)

Prostate Cancer Metastatic

Canada
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)

Castration-Resistant Prostate Cancer

United States, Canada, France, Spain, United Kingdom, Australia, Poland, Germany, Austria, Belgium, Netherlands, Italy, Chile, South Africa, Argentina
Exelixis

Terminated

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)

Pain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

United States, Canada, Australia, United Kingdom, Ireland
British Columbia Cancer Agency

Recruiting

PSMA PET/CT for Assessment of Recurrent Prostate Cancer

Prostatic Neoplasms | Prostate Cancer

Canada
Bayer

Completed

A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety (QOLRAD)

Prostate Cancer

Colombia
Georgetown University

Recruiting

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery (PR-PROS)

Prostate Cancer | Localized Malignant Neoplasm

United States
Arvinas Androgen Receptor, Inc.

Active, not recruiting

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Metastatic

Canada, United States, France, United Kingdom
Agennix

Completed

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Prostate Cancer | Hormone Refractory Prostate Cancer

United States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
British Columbia Cancer Agency
BC Cancer Foundation

Recruiting

LDR vs. HDR Brachytherapy for Prostate Cancer (LDR/HDRmono)

Prostate Cancer

Canada
British Columbia Cancer Agency

Active, not recruiting

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

Prostate Cancer

Canada
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
Dendreon

Completed

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

Prostate Cancer

United States
University Health Network, Toronto

Completed

Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) (ACDC-RP)

Prostate Cancer

Canada
Lawson Health Research Institute
AbbVie; Canadian Association of Radiation Oncology

Active, not recruiting

Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer (HOPE)

Prostate Cancer

Canada
UNC Lineberger Comprehensive Cancer Center
Radiation Therapy Oncology Group

Completed

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

Prostate Cancer

United States
Dendreon

Terminated

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)

Castration-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

Canada
British Columbia Cancer Agency

Completed

CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse (Vitesse)

Prostate Cancer | Interstitial Radiation | High Dose Rate Brachytherapy | Ultrasound-based Planning Compared to CT-based Planning

Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bayer; Dendreon

Completed

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Prostate Cancer

United States
British Columbia Cancer Agency
BC Cancer Foundation

Active, not recruiting

Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy (BrachyQOL)

Prostate Cancer

Canada
University of British Columbia
Vancouver Prostate Centre

Completed

Innovations in the Treatment of Sexual Health Post Prostate Cancer Treatment: Comparing Mindfulness vs. CBT (INTROSPPECT)

Prostatic Neoplasms | Sexual Dysfunctions, Psychological | Sexual Dysfunction, Physiological | Prostate Cancer | Sexual Dysfunction Male | Relationships, Marital

Canada

Clinical Trials on Recurrent Prostate Cancer in Colombia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations